Mr. Cameron Groome reports

MICROBIX SCHEDULES RELEASE OF RESULTS FOR Q1 FISCAL 2025

Microbix Biosystems Inc. expects to file its financial statements and management's disclosure and analysis for the first quarter of fiscal 2025 ended Dec. 31, 2024, prior to the start of trading on Feb. 13, 2025. At 11 a.m. ET on that day, Microbix intends to hold a webinar discussion of Q1 2025 results with its chief executive officer, chief financial officer and chief operating officer.

Investors and shareholders can participate in the webinar, hosted by Adelaide Capital, by registering.

It will also be live streamed to YouTube.

Telephone participation in the webinar can be arranged by contacting Microbix or Adelaide Capital.

A replay of the webinar will also be made available on Adelaide Capital's YouTube channel.

About Microbix Biosystems Inc.

Microbix Biosystems creates proprietary biological products for human health, with over 120 skilled employees and revenues now targeting $2-million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical laboratory proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 and 13485 accredited, United States Food and Drug Administration registered, Australian Therapeutic Goods Administration registered and Health Canada licensed, and provides IVDR-compliant (in vitro diagnostic regulation), CE-marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (such as its DxTM for patient-sample collection).

We seek Safe Harbor.